CBD Products Inc. launches Cannabinoid Balance Pet+ for the growing pet CBD market

Cannabinoid Balance Pet + by CBD Products Inc.

Cannabinoid Balance Pet+ comes as a result of the continued groundswell of knowledge around the endocannabinoid system of pets, the innate ability for their interact with the cannabidiol compound and the growing market opportunity."

SAN DIEGO (PRWEB) July 07, 2021

In response to the growing awareness of the effects of CBD on pets and continued increases in consumer spending on pet care, California based CBD Products Inc. has launched a brand new product specifically for the pet market.

Cannabinoid Balance Pet+ is a broad spectrum CBD tincture specifically designed to help alleviate symptoms in pets who suffer from anxiety, chronic inflammation, arthritis, joint pain, nausea, high blood pressure, and digestion problems.

And the difference between Cannabinoid Balance Pet+ and the majority of other options on the market is that Pet+ uses proprietary NanoZorb™ technology. This nanotechnology helps breakdown the CBD molecules into smaller components and add a coating that allows the lipid-based molecules to become more soluble with higher bioavailability and thus higher efficacy.

Cannabinoid Balance Pet+ tincture is made from organic hemp, non-GMO sunflower lecithin, and coconut MCT oil and comes in a 30mL bottle at 250mg of CBD.

Anthony Tribunella of CBD Products says “The launch of Cannabinoid Balance Pet+ comes as a result of the continued groundswell of knowledge around the endocannabinoid system of pets, and the innate ability for their interact with the cannabidiol compound. It also coincides with a deeper belief that pets should experience the same standard of wellbeing as their owners, something I personally believe in, and which bodes well for the business.”

In the case of CBD, early science continues to show that, just like their human owners, pets—and specifically, dogs—respond well to CBD, showing the alleviation of symptoms of things like pain and inflammation, stress and anxiety, gastrointestinal issues, and psychotic behaviors. But since the research is still in its infancy, we wanted to check: What exactly are the updates coming from recent research?
 
One of the first major studies done on CBD and dogs was published in 2018 by Cornell University showing that administering CBD to dogs with osteoarthritis helped ease the pain for a full 80% of dogs in the study, with no noticeable side effects.

Additionally, in 2018, Colorado State University’s James L. Voss Veterinary Teaching Hospital conducted clinical trials to measure the efficacy of using CBD to reduce the frequency and intensity of seizures in dogs with epilepsy, and preliminary data showed significant promise. With sixteen dogs in the trial, nine received CBD with less than 0.3 percent THC as treatment, while seven received a placebo; both groups were also receiving conventional anti-epileptic drug therapy. According to the study, CBD helped reduce seizure frequency for that group of dogs by 89%, versus the 43% reduction in seizures the placebo group experienced. The study is ongoing, and more results will provide a fuller picture—but as of now, researchers are very optimistic.

While new research is still somewhat slow on the scene, in March of this year, more findings came out of Colorado State University reporting reduced osteoarthritic-related pain in dogs with the use of CBD-rich hemp oil extract. The University conducted a 90-day pilot clinical trial including 37 dogs that had been diagnosed with maladaptive pain related to osteoarthritis. Thirty of the 32 dogs that completed the study showed improved pain metrics. Twenty-three of the dogs were also taking the nerve pain medication gabapentin during the trial and, as a result of the CBD oil, 10 of those dogs were able to stop using gabapentin completely and 11 were able to reduce their daily dose of the drug. 

Another paper, published in May 2020, by researchers at the Centre for Evidence-based Veterinary Medicine at the University of Nottingham in the UK reported that adding specific CBD oils and doses to a regimen of NSAID treatment for dogs with osteoarthritis has the potential to reduce pain, according to owner assessment. Veterinarian assessments did not find significant change, however the paper said they needed improved evidence to make any determinations. 

Finally, this September, a group of veterinary researchers from Baylor College of Medicine, the University of Texas, and Boston University School of Medicine published findings in the journal PAIN from a randomized, double-blind, placebo-controlled study on the effects of daily cannabidiol use in osteoarthritic dogs. According to their findings, the dogs experienced greatly decreased pain and increased mobility.

What some researchers and veterinarians are finding, though, is that it is likely that hemp extracts that have a stronger ratio of THC—something in the ballpark of 1 part THC to 20 parts CBD—along with other cannabinoids and terpenes would be more effective at preventing seizures than isolate extracts, but because of the legal status of cannabis and the associated stigma of THC and its use, those potentially more effective options cannot be studied as of yet, much less administered. 

Anthony Tribunella - Founder, CBD Products Inc; “As the science of CBD in pets continues to gather pace, we are committed to staying at the forefront of product development and science, and are proud to see Cannabinoid Balance Pet + enter into the market.”